Dishman Carbogen Amcis Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Dishman Carbogen Amcis Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Debt, after subtracting cash, equals 95% of its market value (net debt). Lower than 98% of Healthcare companies in India.
- Tangible Assets Ratio: Of every ₹100 the company owns, ₹56 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. Less tangible than 95% of Healthcare companies in India.
- Tangible Net Worth Ratio: Of every ₹100 of net worth, ₹22 is tangible; the rest is goodwill and other intangibles, often from buying other companies. Less tangible than 94% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
1.6×Over the last 3 years its own operating cash covered its investment spending (capex) 1.6 times.
Higher than 60% of Healthcare companies in India.
Cash Locked Ratio
₹39For every ₹100 of sales, ₹39 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹48 tied up three years earlier.
More money tied up than 75% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 53% of Healthcare companies in India.
Growth Efficiency Ratio
₹23Sales grew 24% in 3 years; of every extra ₹100 of sales, ₹23 became extra profit.
Higher than 68% of Healthcare companies in India.
Asset Productivity Ratio
+24% / +26%In 3 years sales changed by +24% while total assets changed by +26%. Both moved at about the same pace.
Balance-sheet strength
Debt Due Cover Ratio
0.4×Debt due within a year is covered 0.4 times by its yearly operating cash.
Lower than 75% of Healthcare companies in India.
Cash Cushion Ratio
−95%Debt, after subtracting cash, equals 95% of its market value (net debt).
Lower than 98% of Healthcare companies in India.
Tangible Assets Ratio
56%Of every ₹100 the company owns, ₹56 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 95% of Healthcare companies in India.
Tangible Net Worth Ratio
22%Of every ₹100 of net worth, ₹22 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 94% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Dishman Carbogen Amcis Limited owes ₹0.44 for every ₹1 it owns. Net profit rose 2908% in the year to Mar 2026.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
137.3Investors pay ₹137.3 for every ₹1 of Dishman Carbogen Amcis Limited's yearly profit, higher than 94% of Healthcare companies in India.
P/B ratio
0.33The share price is 0.33 times Dishman Carbogen Amcis Limited's book value per share, lower than almost all Healthcare companies in India.
Market cap
₹2,195 CrThe total market value of all of Dishman Carbogen Amcis Limited's shares at today's price (share price × number of shares), smaller than 62% of Healthcare companies in India. PosiCap size class: Mini Cap.
Net worth (book value)
₹6,677 CrWhat Dishman Carbogen Amcis Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹425.87Net worth divided by the number of shares. The share price of ₹140.02 is 0.3 times this, which is the P/B above.
Return on equity (ROE)
0.2%Dishman Carbogen Amcis Limited earned 0.2% on its shareholders' money over the last year, lower than 93% of Healthcare companies in India.
Owes vs Owns
0.44×Dishman Carbogen Amcis Limited owes ₹0.44 for every ₹1 it owns (low), higher than 69% of Healthcare companies in India.
Dividend yield
NoneDishman Carbogen Amcis Limited does not currently pay a dividend.
Revenue growth
+9%Revenue rose 9% in the year to Mar 2026, and grew 8% a year on average over 3 years.
Profit growth
+2908%Net profit rose 2908% in the year to Mar 2026.
Profit margin
3.4%Dishman Carbogen Amcis Limited keeps ₹3 of every ₹100 of revenue as net profit.
Cash quality
5.0×Cash from Dishman Carbogen Amcis Limited's business was 5.0× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
1.3×Dishman Carbogen Amcis Limited's operating profit covered its interest costs 1.3 times in the year to Mar 2026.
Cash vs debt
Net debtDishman Carbogen Amcis Limited had ₹2,093 Cr more debt than cash (net debt) at Mar 2026.
Questions
What is Dishman Carbogen Amcis Limited's P/E ratio?
Investors pay ₹137.3 for every ₹1 of Dishman Carbogen Amcis Limited's yearly profit, higher than 94% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Dishman Carbogen Amcis Limited: ₹2,195 Cr ÷ ₹6,677 Cr (31 Mar 2026) = 0.3.
What is Dishman Carbogen Amcis Limited's return on equity?
Dishman Carbogen Amcis Limited earned 0.2% on its shareholders' money over the last year, lower than 93% of Healthcare companies in India.
How much does Dishman Carbogen Amcis Limited owe compared with what it owns?
Dishman Carbogen Amcis Limited owes ₹0.44 for every ₹1 it owns (low), higher than 69% of Healthcare companies in India.
Does Dishman Carbogen Amcis Limited pay a dividend?
No. Dishman Carbogen Amcis Limited does not currently pay a dividend.
Is Dishman Carbogen Amcis Limited's revenue growing?
Revenue rose 9% in the year to Mar 2026, and grew 8% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.